We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
17β-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells.
- Authors
Lai, Tung-Yuan; Chen, Li-Mien; Lin, Jing-Ying; Tzang, Bor-Show; Lin, James; Tsai, Chang-Hai; Lin, Yueh-Min; Huang, Chih-Yang; Liu, Chung-Jung; Hsu, Hsi-Hsien
- Abstract
Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in women are lower than in men. However, it is unknown if 17β-estradiol treatment is sufficient to inhibit prostaglandin E2 (PGE2)-induced cellular motility in human colon cancer cells. Upregulation of cyclooxygenase-2 (COX-2) is reported to associate with the development of cancer cell mobility, metastasis, and subsequent malignant tumor. After administration of inhibitors including LY294002 (Akt activation inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor), or QNZ (NFκB inhibitor), we found that PGE2 treatment increases COX-2 via Akt and ERK1/2 pathways, thus promoting cellular motility in human LoVo cancer cells. We further observed that 17β-estradiol treatment inhibits PGE2-induced COX-2 expression and cellular motility via suppressing activation of Akt and ERK1/2 in human LoVo cancer cells. Collectively, these results suggest that 17β-estradiol treatment dramatically inhibits PGE2-induced progression of human LoVo colon cancer cells.
- Subjects
COLON cancer; ESTRADIOL; PROSTAGLANDINS; CYCLOOXYGENASE 2; GENE expression; CELL migration; ENZYME inhibitors; CANCER cells
- Publication
Molecular & Cellular Biochemistry, 2010, Vol 342, Issue 1/2, p63
- ISSN
0300-8177
- Publication type
Article
- DOI
10.1007/s11010-010-0469-7